Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients under...

Descripción completa

Detalles Bibliográficos
Autores principales: Saltarella, Ilaria, Desantis, Vanessa, Melaccio, Assunta, Solimando, Antonio Giovanni, Lamanuzzi, Aurelia, Ria, Roberto, Storlazzi, Clelia Tiziana, Mariggiò, Maria Addolorata, Vacca, Angelo, Frassanito, Maria Antonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017193/
https://www.ncbi.nlm.nih.gov/pubmed/31936617
http://dx.doi.org/10.3390/cells9010167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017193/
https://www.ncbi.nlm.nih.gov/pubmed/31936617
http://dx.doi.org/10.3390/cells9010167

Ejemplares similares